A future for regulatory science in the European Union: the European Medicines Agency's strategy

P.A. Hines*, R. Janssens, R. Gonzalez-Quevedo, A.I.O.M. Lambert, A.J. Humphreys

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review


After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency's Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.
Original languageEnglish
Pages (from-to)293-294
Number of pages2
JournalNature Reviews Drug Discovery
Issue number5
Publication statusPublished - 1 May 2020

JEL classifications

  • i18 - "Health: Government Policy; Regulation; Public Health"
  • o30 - "Technological Change; Research and Development; Intellectual Property Rights: General"


  • Regulation
  • Medicines
  • Intellectual Property
  • Science
  • R&D
  • European Union

Cite this